News & Analysis on Clinical Trial Services & Contract Research And Development
Chiltern International, one of Europe's leading mid-sized contract research organisations, has opened up an office in Ukraine to tap into a growing market for clinical trial services in central and Eastern Europe.
Healthcare giant Cardinal Health reported revenues up 11 per cent to $14.1 billion (€11.2bn) in the fourth-quarter of 2003, as a strong performance in its pharmaceutical manufacturing services, pharmacy automation and medical product business...
Last year, pharmaceutical companies from India submitted a third of all the Drug Master Files for active pharma ingredients (APIs) received in the US, outstripping their international rivals by a wide margin.
Japanese pharmaceutical companies must build strong, in-house, R&D capabilities in order to survive, according to research from market analyst firm Datamonitor. But this is not simply a matter of spending more money; strategic and organisational...
A commercial unit of the UK Medical Research Council (MRC) has launched a gene-silencing library - based on small interfering RNA (siRNA) - that covers 90 per cent of the genome of the fruitfly Drosophila melanogaster which is widely used in genetic...
Germany's Wacker Specialties has signed an R&D agreement with Finland's Prokaria to bolster its activities in chiral alcohols, used as chemical building blocks by the pharmaceutical industry.
Since they were introduced in the early 1990s, beta interferons have become the standard of care for patients with the neurodegenerative disease multiple sclerosis, but up to a third of MS patients do not derive a benefit from these drugs.
French pharmaceutical company Sanofi-Synthelabo has launched a hostile takeover bid for its larger rival Aventis, in a move which would create a top three drug major.
Israel-headquartered generics company Teva Pharmaceutical Industries has completed its $3.4 billion takeover of US company SICOR, which makes generics and active pharmaceutical ingredients.
Switzerland's Bachem saw its 2003 sales slip by 3 per cent as continued slack demand for research chemicals held back a modest increase in its active pharmaceutical ingredients business.